Consensus Statement Published August, 2020

In the light of the COVID-19 pandemic, the International Workshop on Waldenström Macroglobulinemia (IWWM) Treatment Recommendations Panel has published a consensus statement for the management of Waldenström Macroglobulinemia (WM) patients during this challenging time. The Panel followed the current recommendations by the American Society of Hematology, which have been modified accordingly to fit the specific realities associated with the management of WM. The Panel addressed questions related to treatment initiation, preferred therapies, minimizing visit to clinics and infusions centers, supportive care and guidance for WM patients in clinical trials. It also provided information on timing and appropriateness of testing and management of COVID-19 infected patients, as well as ways to get physicians and patients involved in registry studies that could help others.

Published here in HemaSphere, the publication of the European Hematology Association.

See the EHA publication here

ASH publication in August, 2020

The American Society of Hematology published similar, but slightly different guidelines.  This article in Medscape points out some of the differences, and references the original ASH guidelines.

See the Medscape publication here